Mandate

Vinge advises Precio Fishbone in connection with the sale of shares in a subsidiary company

Vinge advises Precio Fishbone AB (publ) (”Precio Fishbone”) in connection with the sale of approximately 80.1 per cent of the shares in the subsidiary Precio Fishbone Systems AB ("Omnia"), including the product Omnia Digital Workplace, to Monterro.

Omnia Digital Workplace has been awarded in several different international contexts and has for six consecutive years been ranked as the market's best SaaS product for creating a modern digital workplace.

Monterro acquires a majority stake of approximately 80.1 per cent in Omnia from Precio Fishbone while Precio Fishbone retains a minority stake of approximately 19.9 per cent. Omnia has been created through a restructuring whereby all operations and employees related to the product Omnia Digital Workplace have been transferred from Precio Fishbone to the previously wholly owned subsidiary Omnia. All shares in Omnia are transferred to a company that will be indirectly owned by Monterro and Precio Fishbone. The purchase price for the approximately 80.1 per cent of the shares in Omnia indirectly transferred to Monterro amounts to SEK 168 million. Omnia also owns Omnia Systems Ltd (Vietnam), Precio Fishbone Canada Inc, Precio Fishbone Danmark ApS and has a branch in Germany.

Vinge’s team consisted of Matthias Pannier, Gustav Persson, Maximilian Bengtsson (M&A), Dain Hård Nevonen, William Kåge (Capital Markets), Mathilda Persson (Corporate Commercial), Rebecka Målquist (Intellectual Property) and Fanny Askelöf (Transaction Support Specialist).

Related

Vinge advised Precise Biometrics

Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026